Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have been given a consensus rating of “Moderate Buy” by the nine brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $21.38.

Several research analysts have issued reports on YMAB shares. Oppenheimer assumed coverage on Y-mAbs Therapeutics in a research report on Monday, November 18th. They issued an “outperform” rating and a $23.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th. BMO Capital Markets dropped their target price on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, August 13th. Morgan Stanley decreased their price target on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a research note on Tuesday, August 13th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th.

Y-mAbs Therapeutics Price Performance

Shares of NASDAQ YMAB opened at $10.56 on Thursday. The stock has a fifty day moving average price of $13.69 and a 200 day moving average price of $12.84. Y-mAbs Therapeutics has a 1-year low of $5.31 and a 1-year high of $20.90. The company has a market cap of $472.98 million, a PE ratio of -19.56 and a beta of 0.68.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The business had revenue of $18.46 million during the quarter, compared to analysts’ expectations of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same period in the prior year, the firm posted ($0.18) EPS. Analysts anticipate that Y-mAbs Therapeutics will post -0.64 earnings per share for the current fiscal year.

Insider Activity at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 65,000 shares of the stock in a transaction on Friday, September 13th. The stock was sold at an average price of $13.47, for a total transaction of $875,550.00. Following the transaction, the insider now owns 97,681 shares of the company’s stock, valued at $1,315,763.07. This represents a 39.96 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 22.50% of the company’s stock.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Several large investors have recently added to or reduced their stakes in the business. State Street Corp increased its stake in shares of Y-mAbs Therapeutics by 50.4% during the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after acquiring an additional 405,169 shares during the last quarter. Caligan Partners LP grew its holdings in Y-mAbs Therapeutics by 105.3% in the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock valued at $15,718,000 after purchasing an additional 613,175 shares during the period. Geode Capital Management LLC increased its position in Y-mAbs Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock worth $10,699,000 after purchasing an additional 47,846 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Y-mAbs Therapeutics by 15.7% during the second quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock worth $5,853,000 after purchasing an additional 65,732 shares during the period. Finally, Millennium Management LLC boosted its holdings in shares of Y-mAbs Therapeutics by 23.8% in the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after purchasing an additional 67,233 shares during the last quarter. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.